Status: Recruiting
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Evaluate efficacy and safety of ADI-PEG 20 in patients with high-argininephenotypic and HCC
Participants needed: 300
Trial details
Phase: Phase 3Age: 18-99Biological sex: AllType: InterventionalSponsor: Polaris GroupUpdated: Dec 18, 2025Locations: 11
Eligibility criteria
Prior diagnosis of HCC confirmed by radiology, histology, or cytology. [+23]
Candidate for potential curative therapies (i.e., resection or transplantation)... [+15]